Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins

JERUSALEM, July 11, 2012 /PRNewswire/ –

Technology to orally administer medications offers far-reaching impact in healthcare
industry

Announcing its third patent approval since the beginning of the calendar year, Oramed
Pharmaceuticals Inc. (OTCBB:ORMP.OB) (www [http://www.oramed.com ] .
[http://www.oramed.com ] oramed [http://www.oramed.com ] . [http://www.oramed.com ] com
[http://www.oramed.com ]), a developer of oral drug delivery systems
[http://oramed.com/index.php?page=12 ], announced today that its patent, titled “Methods
and Compositions for Oral Administrations of Proteins,” was approved by the New Zealand
Patent Office. This patent covers a core concept in the Company’s technology and is
Oramed’s second patent to be granted in New Zealand, the first being that of its “Methods
in the Oral Administration of Exenatide.” Oramed’s portfolio now consists of 4 issued
patents and 33 patents pending for its technologies and products.

The current method of administration for peptide-formulated medications is most often
via injection. The ability to administer these medications orally offers far-reaching
impact on patient compliance and health costs with potential to traverse a broad range of
ailments and drug therapies, including diabetes medications, vaccines
[http://www.oramed.com/ufiles/Knobias article Oct 14 2009.pdf ], and others. Oramed is
currently applying its oral delivery technology to its two flagship products – an oral
insulin capsule [http://oramed.com/index.php?page=14 ] (ORMD-0801) and an oral GLP-1
analog capsule [http://oramed.com/index.php?page=16 ] (ORMD-0901) – both of which are
indicated for diabetes.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions
for drugs and vaccines currently delivered via injection. Established in 2006, Oramed’s
technology is based on over 25 years of research by top research scientists at Jerusalem’s
Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes
through its patented flagship product, an orally ingestible insulin capsule currently
approaching FDA-approved Phase 2 clinical trials, and with its GLP-1 analog capsule,
currently entering Phase 2a trials. The company’s corporate and R&D headquarters are based
in Jerusalem.

The company’s fact sheet can be viewed here
[http://oramed.com/ufiles/Oramed-fact-sheet-July-8-2012.pdf ].

For more information, the content of which is not part of this press release, please
visit http://www.oramed.com

SafeHarbor for Forward-looking Statements: This press release contains forward-looking
statements. For example, we are using forward-looking statements when we discuss the
possibility of increased patient compliance and lower healthcare costs resulting from our
products, or therapies for which our drug could be indicated. These forward-looking
statements are based on the current expectations of the management of Oramed only, and are
subject to a number of factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements, including the risks and
uncertainties related to the progress, timing, cost, and results of clinical trials and
product development programs; difficulties or delays in obtaining regulatory approval or
patent protection for our product candidates; competition from other pharmaceutical or
biotechnology companies; and our ability to obtain additional funding required to conduct
our research, development and commercialization activities. In addition, the following
factors, among others, could cause actual results to differ materially from those
described in the forward-looking statements: changes in technology and market
requirements; delays or obstacles in launching our clinical trials; changes in
legislation; inability to timely develop and introduce new technologies, products and
applications; lack of validation of our technology as we progress further and lack of
acceptance of our methods by the scientific community; inability to retain or attract key
employees whose knowledge is essential to the development of our products; unforeseen
scientific difficulties that may develop with our process; greater cost of final product
than anticipated; loss of market share and pressure on pricing resulting from competition;
laboratory results that do not translate to equally good results in real settings; our
patents may not be sufficient; and final that products may harm recipients, all of which
could cause the actual results or performance of Oramed to differ materially from those
contemplated in such forward-looking statements. Except as otherwise required by law,
Oramed undertakes no obligation to publicly release any revisions to these forward-looking
statements to reflect events or circumstances after the date hereof or to reflect the
occurrence of unanticipated events. For a more detailed description of the risks and
uncertainties affecting Oramed, reference is made to Oramed’s reports filed from time to
time with the Securities and Exchange Commission.

.

        Company and Investor Relations Contact:
        Aviva Sherman
        USA: +1 646-240-4193
        Int'l: + 972-2-566-0001
        + 972-54-792-4438
        E-mail: aviva@oramed.com

SOURCE Oramed Pharmaceuticals Inc.